Camilla Kilbane, MD
Neurology · San Francisco, CANPI 1659526093
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,701 of the $113,874 with a category attached, or 73.5%. Teva Pharmaceuticals USA, Inc. accounts for 69.5% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $29,633, 2.1 times the $14,316 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $389.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$79K
- Acorda Therapeutics, Inc$17K
- Medtronic$8K
- AbbVie$2K
- Kyowa Kirin, Inc.$2K
- Amneal Pharmaceuticals LLC$2K
- plus $3K from 33 others
Across 24 payments — averaging $3780.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$33K
- Neurocrine Biosciences, Inc.$21K
- Amneal Pharmaceuticals LLC$18K
- Medtronic$17K
- Abbott$2K
What the payments were for
- Consulting fees$14,38013%
- Speaking & faculty fees$83,70174%
- Travel & lodging$7,8167%
- Food & beverage$7,7867%
- Education$1900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,874 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 98 | $203,480 |
| NuplazidPimavanserin Tartrate | 11 | $54,777 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 425 | $17,312 |
| Rasagiline Mesylate | 26 | $12,628 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 264 | $7,257 |
| Entacapone | 18 | $5,204 |
| AmantadineAmantadine Hcl | 84 | $4,609 |
| Primidone | 101 | $2,500 |
| Ropinirole Hcl | 52 | $1,921 |
| Baclofen | 38 | $1,054 |
| Gabapentin | 67 | $932 |
| Propranolol Hcl | 48 | $909 |
| Ropinirole ErRopinirole Hcl | 11 | $878 |
| Levetiracetam | 14 | $498 |
| Topiramate | 30 | $371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $1,732 | $203,48098 claims |
| Acadia Pharmaceuticals IncNuplazid | $242 | $54,77711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.